Genomic and immune characteristics of <i>HER2</i>‐mutated non‐small‐cell lung cancer and response to immune checkpoint inhibitor‐based therapy
Hai‐Yan Tu(Jiangnan University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Qiuxiang Ou(Genesee Community College), Yue‐Li Sun(Guangdong Academy of Medical Sciences), Xiaotian Zhao, Xu‐Chao Zhang(Guangdong Academy of Medical Sciences), Mei-Mei Zheng(Guangdong Provincial People's Hospital), Wen‐Zhao Zhong(Guangdong Academy of Medical Sciences), Qing Zhou(Jiangnan University), Yichen Zhang(Peking University), Si‐Yang Maggie Liu(University of Arizona), Jin‐Ji Yang(Guangdong General Hospital), Jia‐Xin Lin(Guangdong Academy of Medical Sciences), Si-Pei Wu(Guangdong Academy of Medical Sciences), Lingling Yang(Beijing Institute of Petrochemical Technology), Xiaoyan Bai(Dalian Medical University), E‐E Ke(Guangdong Academy of Medical Sciences), Dongqin Zhu(Wake Forest University), Y.-S. Li(Guangdong Academy of Medical Sciences), Chong‐Rui Xu(Guangdong Academy of Medical Sciences), Bing‐Chao Wang(Guangdong Academy of Medical Sciences), Kai Yin(Guangdong Academy of Medical Sciences)
Cited by 9
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k